[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649040":3},{"organization":4,"armGroups":7,"interventions":68,"overallOfficials":74,"centralContacts":79,"locations":85,"responsibleParty":101,"collaborators":74,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":74,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":111,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":74,"studyType":117,"phases":118,"briefSummary":120,"conditions":121,"keywords":74,"overallStatus":88,"whyStopped":74,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"Atea Pharmaceuticals, Inc.","INDUSTRY",[8,14,20,24,28,32,36,40,44,48,52,56,60,64],{"label":9,"type":10,"description":11,"interventionNames":12},"AT-587 Dose 1 (Day 1)","EXPERIMENTAL","AT-587 administered orally, dose 1 on Day 1",[13],"Drug: AT-587",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo -Dose 1 (Day 1)","PLACEBO_COMPARATOR","Matching placebo dose 1 administered orally on Day 1",[19],"Other: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"AT-587 Dose 2 (Day 1 and Day 7)","AT-587 administrated orally, dose 2 on Day 1 and Day 7",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Placebo-Dose 2 (Day 1 and Day 7)","Matching placebo dose 2 administered orally on Day 1 and Day 7",[19],{"label":29,"type":10,"description":30,"interventionNames":31},"AT-587 Dose 3 - (Day 1)","AT-587 administered orally, dose 3 on Day 1",[13],{"label":33,"type":16,"description":34,"interventionNames":35},"Placebo - Dose 3 - (Day 1)","Matching placebo dose 3 administered orally on Day 1",[19],{"label":37,"type":10,"description":38,"interventionNames":39},"AT-587 Dose 4 - (Day 1)","AT-587 administered orally, dose 4 on Day 1",[13],{"label":41,"type":16,"description":42,"interventionNames":43},"Placebo - Dose 4- (Day 1)","Matching placebo dose 4 administered orally on Day 1",[19],{"label":45,"type":10,"description":46,"interventionNames":47},"AT-587 - Dose 5 (Day 1-7)","AT-587 - administered orally, dose 5 (QD) for 7 days",[13],{"label":49,"type":16,"description":50,"interventionNames":51},"Placebo- Dose 5 (QD) (Day 1-7)","Matching placebo dose 5 administered orally once daily (QD) for 7 days",[19],{"label":53,"type":10,"description":54,"interventionNames":55},"AT-587 - Dose 6 split (BID) (Day 1-7)","AT-587 administered orally, dose 6 daily split (BID) for 7 days",[13],{"label":57,"type":16,"description":58,"interventionNames":59},"Placebo - Dose 6 (BID) (Day 1-7)","Matching placebo administered orally dose 6 daily split (BID) for 7 days",[19],{"label":61,"type":10,"description":62,"interventionNames":63},"AT-587 - Dose 7 (QD) or split (BID) daily (Day 1-7)","AT-587 administered orally, dose 7 (QD) or split (BID) for 7 days",[13],{"label":65,"type":16,"description":66,"interventionNames":67},"Placebo - Dose 7 (QD) or split (BID) (Day 1-7)","Matching placebo administered orally, dose 7 daily (QD) or split (BID) for 7 days",[19],[69,75],{"type":70,"name":71,"description":72,"armGroupLabels":73,"otherNames":74},"DRUG","AT-587","Parallel Assignment",[45,53,61,9,21,29,37],null,{"type":76,"name":77,"description":72,"armGroupLabels":78,"otherNames":74},"OTHER","Placebo",[33,41,57,65,15,49,25],[80],{"name":81,"role":82,"phone":83,"phoneExt":74,"email":84},"Clinical Trials Administrator","CONTACT","888-481-1607","AteaClinicalTrials@ateapharma.com",[86],{"facility":87,"status":88,"city":89,"state":74,"zip":90,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":98,"contacts":99},"Atea Study Site","RECRUITING","Edegem","2650","Belgium","BE",{"type":94,"coordinates":95},"Point",[96,97],4.44504,51.15662,{"lat":97,"lon":96},[100],{"name":87,"role":82,"phone":74,"phoneExt":74,"email":74},{"type":102,"investigatorFullName":74,"investigatorTitle":74,"investigatorAffiliation":74,"oldNameTitle":74,"oldOrganization":74},"SPONSOR","100649040","phase-1-study-of-at-587-in-healthy-subjects-100649040",false,"NCT07728487","Study of AT-587 in Healthy Subjects","A Phase 1, First-in-Human (FIH), Single-center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of AT-587 in Healthy Adult Participants","Inclusion Criteria:\n\n* Body mass index (BMI) of 18-29 kg\u002Fm2\n* Must agree to use protocol-specified methods of contraception\n* Negative pregnancy test\n* Willing to comply with the study requirements and to provide written informed consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Abuse of alcohol or drugs\n* Use of other investigational drugs within 30 days of dosing\n* Other clinically significant medical conditions",true,"ALL","18 Years","65 Years",{"count":115,"type":116},62,"ESTIMATED","INTERVENTIONAL",[119],"PHASE1","This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-587 in healthy subjects",[122],"Hepatitis E","2026-07-22",{"date":125,"type":126},"2026-07-27","ACTUAL",{"date":128,"type":126},"2026-07-13",{"date":130,"type":116},"2026-12",{"name":5,"class":6},1]